Shares of BioHarvest Sciences, which uses its proprietary botanical synthesis technology to develop therapeutic solutions, advanced close to 12% on the Canadian Securities Exchange (CSE) and almost 14% over the counter in New York on Thursday, November 7. The gains followed the company’s announcement that Nasdaq had approved its listing…